Key Points
- Liquidia CEO Roger Jeffs sold 25,000 shares on May 26 at an average price of $60.38, totaling about $1.51 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Jeffs has been actively reducing his stake, with several other recent share sales in May and April. After the latest transaction, he still held about 1.05 million shares valued at roughly $63.3 million.
- Liquidia’s stock has surged, opening at $60.10 and trading near its 52-week high of $62.30. The company also recently beat quarterly earnings and revenue expectations, and analysts currently have a Moderate Buy consensus rating.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $60.38, for a total value of $1,509,500.00. Following the transaction, the chief executive officer owned 1,048,095 shares in the company, valued at $63,283,976.10. This represents a 2.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Roger Jeffs also recently made the following trade(s):
- On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $61.13, for a total value of $1,528,250.00.
- On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $58.65, for a total value of $1,466,250.00.
- On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total value of $1,426,000.00.
- On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $56.29, for a total value of $1,407,250.00.
- On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $41.50, for a total value of $1,037,500.00.
- On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
- On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total value of $1,002,500.00.
- On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.
- On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total value of $1,003,500.00.
- On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
Liquidia Stock Performance
Shares of NASDAQ LQDA opened at $60.10 on Wednesday. The business's 50-day moving average price is $43.00 and its two-hundred day moving average price is $37.80. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a one year low of $11.85 and a one year high of $62.30. The company has a market capitalization of $5.34 billion, a P/E ratio of 429.32 and a beta of 0.41.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The business's revenue for the quarter was up 4187.1% compared to the same quarter last year. Analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.
Institutional Trading of Liquidia
A number of institutional investors and hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the fourth quarter worth about $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia during the 2nd quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia during the 3rd quarter worth about $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia during the 3rd quarter worth about $34,000. Finally, Covestor Ltd lifted its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on LQDA shares. BTIG Research boosted their target price on Liquidia from $50.00 to $59.00 and gave the company a "buy" rating in a research note on Monday, May 11th. Oppenheimer boosted their price target on Liquidia from $16.00 to $19.00 and gave the stock an "underperform" rating in a research report on Thursday, March 12th. Wall Street Zen raised Liquidia from a "buy" rating to a "strong-buy" rating in a research report on Saturday, May 16th. Wells Fargo & Company boosted their price target on Liquidia from $51.00 to $62.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Liquidia in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $49.33.
Read Our Latest Report on LQDA
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
